Biotech Values

[DewDiligence]

FDA approves AZN’s Tagrisso for first-line metastatic or locally-advanced NSCLC with EGFR exon-19 deletions or exon-21 L858R mutations:

https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-EGFR-mutated-non-small-cell-lung-cancer.html

The approval is based on a phase-3 trial where Tagrissso showed statsig better PFS than Tarceva/Iressa (#msg-133354651).

Until now, Tagrisso was FDA-approved only for second-line NSCLC patients with the T790M EGFR mutation (#msg-118475723).